Structure Therapeutics at AACR 2025: Promising Innovations in Cancer Therapies
- Domain Therapeutics will present DT-7012 and DT-9081 at AACR 2025, focusing on innovative GPCR-targeted cancer therapies.
- DT-7012 targets CCR8 to deplete tumor-resident Tregs, enhancing immune responses against cancer.
- DT-9081, an EP4 receptor antagonist, shows promise in improving anti-tumor immunity with favorable Phase I results.
Innovative Advances in Cancer Therapy: Domain Therapeutics Prepares for AACR 2025
Domain Therapeutics is poised to make significant contributions to the oncology landscape at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled for April 25-30 in Chicago. The company focuses on developing therapies targeting G protein-coupled receptors (GPCRs), and its presentations will highlight two promising oncology programs: DT-7012, an anti-CCR8 antibody, and DT-9081, an EP4 receptor antagonist. These developments reflect Domain's commitment to advancing cancer treatment through novel receptor-targeted strategies.
DT-7012 represents a notable innovation as a fully humanized monoclonal antibody specifically designed to target CCR8, a receptor predominantly found on tumor-resident regulatory T cells (Tregs). Tregs are known to suppress anti-tumor immune responses, thereby hindering effective cancer treatment. The findings presented at AACR will detail DT-7012's binding characteristics and its efficacy in depleting Tregs, providing a strong foundation for its clinical development. This presentation, scheduled for April 27, 2025, is anticipated to shed light on how DT-7012 can enhance the immune system's ability to combat tumors, marking a significant step in the evolution of immuno-oncology therapies.
In addition to DT-7012, Domain Therapeutics will also discuss DT-9081, an EP4 receptor antagonist aimed at counteracting immune suppression driven by prostaglandin E2 (PGE2). Preliminary Phase I clinical results suggest that DT-9081 possesses a favorable safety profile, linear pharmacokinetics, and effective dose-dependent inhibition of EP4 receptor signaling. This presentation, set for April 28, 2025, will highlight the recommended Phase II dose, reinforcing the potential of DT-9081 in enhancing anti-tumor immunity. Together, these programs illustrate Domain Therapeutics' strategic focus on GPCRs to reshape the tumor microenvironment and improve patient outcomes.
In addition to the two key programs, Domain will also showcase insights from its PAR2 biased negative allosteric modulator program. This research underscores the transformative potential of GPCRs in enhancing anti-tumor immunity, further establishing Domain as a leader in innovative cancer therapies. The findings presented at AACR 2025 will likely resonate with the scientific community, emphasizing the importance of deep receptor biology in developing effective oncology treatments.
With these developments, Domain Therapeutics reaffirms its dedication to pushing the boundaries of cancer care, aiming to deliver groundbreaking therapies that can change the treatment paradigm for patients battling cancer.
